Anti-BCMA CAR mRNA-LNP

Item Information

Catalog #

Size

Price

Description

BCMA (B cell maturation antigen), also known as CD269, TNFRSF-17, is an ideal target antigen for novel multiple myeloma therapy due to its highly selective expression in malignant plasma cells. BCMA is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor and is encoded by the human TNFRSF17 gene. This receptor is preferentially expressed on mature B lymphocytes and is important for B cell development and autoimmune responses. This receptor has been shown to specifically bind tumor necrosis factor (ligand) superfamily member 13b (TNFSF13B/TALL-1/BAFF), leading to activation of NF-κB and MAPK8/JNK. For targeting BCMA, chimeric antigen receptor (CAR)-modified T-cell therapy is one of the most common treatment modalities. This product is designed as a tool for the delivery and expression of anti-BCMA CAR mRNA for research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of anti-BCMA CAR mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. The anti-BCMA CAR in this product is approximately 56 kD and consists of anti-BCMA scFv (single-chain variable fragment) linked to a second-generation CAR (chimeric antigen receptor) containing the CD8 hinge and transmembrane domain and 4-1BB and CD3ζ signaling domains. The full-length amino acid sequence of this anti-BCMA CAR mRNA-LNP product is available upon request.

Product Overview

Composition

mRNA-LNPs suspended in PBS (-Ca, -Mg) (pH: 7.0-7.4).

Cell Type Tested

HEK293S

Application & Handing

Upon receiving product, briefly pulse spin before opening to ensure product is at bottom of container. It is important not to spin for too long as this may rupture mRNA-LNPs. Do not vortex. Work with mRNA-LNPs on ice and minimize the time that the product spends at room temperature. After handling the product during experiments, return immediately to ice. mRNA-LNP products should only be handled with certified RNase-free reagents and consumables. Use of filtered pipette tips is highly recommended.

Storage

4°C; ice

Product Image

Anti-Human-BCMA CAR Expression in T-cells

Figure 1: BCMA CAR expression in T-cells transfected by PM-LNP-0017, checked by FACS 48 hours post transfection. Cells were stained by 1° ab: Jackson ImmunoResearch Biotin-SP (long spacer) AffiniPure F(ab’)2 Fragment Goat Anti-mouse IgG, F(ab’)2 fragment specific; 2° ab: Biolegend PE-Streptavidin. Transfected cells were gated by non-transfected T-cells cells grown under identical conditions. Cell morphology may be affected after transfection.

For Research Use Only. Not for use in diagnostic procedures.